Table 2.
PAR Levels in Intracranial MDA-MB-231Br, SUM149, or MDA-MB-436 Tumors From Mice Treated With Daily Vehicle or Niraparib by Oral Gavage for 2 Weeks, or MDA-MB-436 Cells Treated With Niraparib In Vitro
| Model | In vivo or in vitro | Vehicle | Niraparib | ||||
|---|---|---|---|---|---|---|---|
| Mean | SD | n | Mean | SD | n | ||
| MDA-MB-231Br | In vivo | 821.5 | 777.3 | 5 | 1248.0 | 1327.2 | 6 |
| SUM149 | In vivo | 4054.5 | 349.1 | 2 | 433.1* | 122.5 | 3 |
| MDA-MB-436 | In vivo | 195.2 | 59.6 | 3 | 145.7 | 61.9 | 3 |
| In vitro | 3821.1 | 1955.4 | 3 | 248.2* | 106.6 | 3 |
Concentrations are normalized as picogram PAR per microgram tissue as assessed by ELISA.
*Significantly lower PAR levels in tumors or cells treated with niraparib compared to controls.